Empagliflozin improves high-sensitive cardiac troponin-I and high-density lipoprotein cholesterol in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD Trial
ConclusionEmpagliflozin compared to placebo was superior in reducing circulating hs-cTnI that may indicate improvements in cardiomyocytes function in patients with T2DM and CAD. Moreover, empagliflozin had a modest impact on the serum lipid profile biomarkers.Trial registrationThe original EMPA-CARD study has been registered in Iranian Registry of Clinical Trials.www.IRCT.ir, Identifier: IRCT20190412043247N2. Registration Date: 6/13/2020. Registration timing: prospective.
Source: Journal of Diabetes and Metabolic Disorders - Category: Endocrinology Source Type: research
More News: Cardiology | Cholesterol | Clinical Trials | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Empagliflozin | Endocrinology | Heart | Iran Health | Jardiance | SGLT2 Inhibitors | Sodium | Study